Clinical Trial Update: Keynatinib in Treated Patients With NSCLC and Brain Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial of Keynatinib in previously treated non-small cell lung cancer with brain metastases has completed; the update does not detail results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Keynatinib (Keynatinib)

Snippet

Sponsor: Medolution Ltd. | Conditions: Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases | Phase 2 | Status: COMPLETED